Inspections, Compliance, Enforcement, and Criminal Investigations
CIDEC Corporation 31-Oct-02
Department
of Health and Human Services Public
Health Service
New York District
Food & Drug Administration
158-15 Liberty Avenue
Jamaica, NY 11433
October 31, 2002
WARNING LETTER NYK 2003-03
CERTIFIED MAIL
RETURN RECEIPT REQUESTED
Nelson R. Irwin, President
CIDEC Corporation
1466 Clark St. Road
Auburn, New York 13021
Dear Mr. Irwin:
An inspection of your drug manufacturing facility located
at 5776 Oakwood Road, Auburn, New York, conducted by Food and Drug Administration
(FDA) investigators between September 3 and 12, 2002, found significant deviations
from FDA?s regulations establishing current good manufacturing practices (cGMPs)
for finished pharmaceuticals (Title 21, Code of Federal Regulations [C.F.R.],
Part 211). Such deviations cause the
Our investigators found the following deviations:
1) Your facility has no quality control unit, in
violation of 21 C.F.R. 211.22.
2) You have failed to test each lot of components for conformity
with appropriate written specifications, as required by 21 C.F.R.211.84. The
cGMP regulations allow you, as an alternative, to accept reports of analysis
from the component supplier, but such reports were available for only one
lot each of iodine concentrate and a buffer.
3) You have no written procedures that identify the drug
product with a lot or control number that permits determination of the history
of the manufacture and control of the batch, as required by 21 C.F.R. 211.130.
At least one finished product tote containing 220 gallons of CHX Plus Sanitizing
Teat Dip lacked a lot number.
4) You have failed to conduct finished product testing
on the CHX Plus Sanitizing Teat Dips, as required by 21 C.F.R. 211.165(a).
5) You have failed to establish finished product test
specifications for the CHX Plus Sanitizing Teat Dip and the Iodine Teat Dips,
as required by 21 C.F.R. 211.165(c).
6) You have failed to establish a written testing
program designed to assess the stability characteristics of the teat dips, as
required by 21 C.F.R. 211.166(a).
7) You have failed to prepare batch production and
control records, as required by 21 C.F.R. 211.188. For example:
a) There are no batch records for the CHX Plus
Sanitizing Teat Dip, which your production sheets indicate was made on June 14,
August 14, and August 30, 2002.
b) You do not routinely record ingredient lot numbers.
8) You have failed to maintain complete laboratory
records in compliance with 21 C.F.R 211.194(b). Specifically, there are no
records documenting the reason for modifying the test for iodine and to verify that
the results are as accurate and reliable as the previous method.
You should take prompt action to correct these
violations and to establish procedures to prevent their recurrence. Please
reply to this letter in writing within 15 working days of the steps you are
taking to correct the violations. Correspondence concerning this matter should
be directed to the Food and Drug Administration, 300 Hamilton Ave., White
Plains, New York 10601, Attention: Richard T. Trainor, Compliance Officer.
Failure to correct these violations promptly may result
in regulatory action, such as seizure and/or injunction, without further informal
notice. In addition, FDA advises other federal agencies of the issuance of
all Warning Letters about drugs and medical devices so that they may take
this information into account when considering
This letter is not intended to list all violations at
your facility. As a manufacturer of finished pharmaceuticals, you are
responsible for assuring that your overall operation and the products you
manufacture and distribute are in compliance with the law.
Sincerely yours,
/s/
Cindy Mauyewski for Jerome G. Woyshner
District Director
